Minerva Neurosciences (NASDAQ:NERV) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report released on Monday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $5.00 target price on shares of Minerva Neurosciences in a research report on Wednesday, February 26th.

Minerva Neurosciences Trading Up 0.3 %

NASDAQ:NERV opened at $1.62 on Monday. The company has a 50-day moving average of $1.62 and a 200-day moving average of $2.01. Minerva Neurosciences has a twelve month low of $1.15 and a twelve month high of $3.69. The firm has a market cap of $11.29 million, a price-to-earnings ratio of -3.67 and a beta of -0.50.

Minerva Neurosciences (NASDAQ:NERV) last posted its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.49. On average, research analysts forecast that Minerva Neurosciences will post -0.3 earnings per share for the current year.

Institutional Investors Weigh In On Minerva Neurosciences

A number of large investors have recently made changes to their positions in NERV. Apella Capital LLC acquired a new stake in Minerva Neurosciences during the 1st quarter valued at $35,000. Citadel Advisors LLC raised its position in Minerva Neurosciences by 49.5% during the fourth quarter. Citadel Advisors LLC now owns 25,764 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 8,525 shares during the period. Finally, Northern Trust Corp lifted its stake in Minerva Neurosciences by 60.0% in the 4th quarter. Northern Trust Corp now owns 36,878 shares of the biopharmaceutical company’s stock worth $82,000 after acquiring an additional 13,829 shares in the last quarter. Institutional investors and hedge funds own 34.56% of the company’s stock.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.